Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
May 16, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and...
Amarin to Present at Two Upcoming Investor Conferences
May 12, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, will...
Amarin Reports First Quarter 2022 Financial Results and Provides Business Update
May 04, 2022 07:00 ET
|
Amarin Corporation plc
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European...
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)
May 03, 2022 08:00 ET
|
Amarin Corporation plc
The latest prespecified and post hoc sub-analysis of the landmark REDUCE-IT® study, published today in the Journal of the American College of Cardiology (JACC), demonstrated that VASCEPA® (icosapent...
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)
April 26, 2022 08:49 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today its partner HLS Therapeutics has completed negotiations with Canada’s...
Amarin получает компенсацию за VAZKEPA® в Швеции
April 21, 2022 17:58 ET
|
Amarin Corporation plc
Отмечает первое возмещение затрат на оценку технологий здравоохранения (HTA) в Европе и инициирует следующий этап стратегии роста компании Компания предоставляет обновленную...
Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022
April 19, 2022 07:30 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior...
Последний анализ показывает, что VASCEPA® (икозапент этил) значительно снижает риск потенциально фатальных сердечно-сосудистых осложнений у пациентов с предшествующим чрескожным коронарным вмешательством
April 05, 2022 14:05 ET
|
Amarin Corporation plc
Новый субанализ постфактум знаменательного исследования REDUCE-IT, опубликованный в Journal of the American Heart Association (JAHA), показал, что VASCEPA® снижает на 34% риск инсультов, сердечных...
Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes
April 01, 2022 07:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced in vitro research results suggesting that Eicosapentaenoic Acid (EPA),...
Amarin ontvangt vergoeding voor VAZKEPA® in Zweden
March 29, 2022 13:52 ET
|
Amarin Corporation plc
Mijlpaal voor eerste evaluatie van gezondheidstechnologie (HTA) voor vergoeding in Europa en start van de volgende fase van de groeistrategie van het bedrijf Bedrijf deelt voortgangsupdate over...